FDA Approves First Oral Liquid Desmopressin Solution for Central Diabetes Insipidus
Key Insights
Eton Pharmaceuticals (search) received FDA approval for DESMODA (search), the first and only FDA-approved oral liquid formulation of desmopressin for central diabetes insipidus (search) management.
The ready-to-use oral solution eliminates tablet splitting and crushing, enabling precise individualized dosing for patients of all ages with this rare endocrine condition.
DESMODA (search) targets an estimated 13,000 U.S. patients with central diabetes insipidus (search) and is projected to achieve peak annual sales of $30-50 million.
Eton Pharmaceuticals (search) announced FDA approval of DESMODA (search) (desmopressin acetate) Oral Solution, marking the first and only FDA-approved oral liquid formulation of desmopressin for managing central diabetes insipidus (search), also known as arginine vasopressin deficiency (search) (AVP-D). The approval addresses a critical need for precise dosing in a rare condition affecting more than 13,000 patients in the United States, including approximately 3,000-4,000 pediatric patients.
Novel Formulation Addresses Clinical Challenges
DESMODA (search) is supplied as a ready-to-use oral solution (0.05 mg/mL) that eliminates the need for tablet splitting, crushing, refrigeration, mixing, or shaking. This formulation directly addresses longstanding challenges in central diabetes insipidus (search) management, where effective long-term treatment depends on accurately matching desmopressin dosing to each patient's diurnal pattern of water balance.
"In central diabetes insipidus (search), effective long-term management depends on accurately matching desmopressin dosing to each patient's diurnal pattern of water balance," said Sean Brynjelsen, Chief Executive Officer of Eton Pharmaceuticals (search). "Historically, clinicians have primarily relied on formulations that were not designed for fine dose adjustments or had other administration issues, and both clinicians and families often had to rely on workarounds."
Clinical Expert Endorsement
Dr. Lewis Blevins, Director of the California Center for Pituitary Disorders and Professor of Medicine and Neurological Surgery at the University of California, San Francisco, emphasized the clinical significance of the liquid formulation. "Central diabetes insipidus (search) requires careful, individualized management, where dosing precision and flexibility truly matter. Having a liquid formulation of desmopressin has the potential to meaningfully support how we initiate and manage therapy."
Patient advocacy organizations have also welcomed the development. Muriël Marks, board member of Worldwide Adrenal and Pituitary Organizations (WAPO), noted that "a liquid option like DESMODA (search) is a meaningful improvement because it helps make sure that the dose is always right, every time. This is very important in cases where the wrong dose can have a big impact."
Market Potential and Commercial Strategy
Eton projects DESMODA (search) will achieve peak annual sales of $30-50 million, representing what the company describes as "one of the most important product launches in Eton's history." The product benefits from patent protection extending through 2044, providing long-term market exclusivity.
The commercial launch is scheduled for March 9th, with distribution exclusively through Anovo (search), a specialty pharmacy dedicated to serving patients with rare and chronic conditions. Eton's existing pediatric endocrinology rare disease specialists, who currently promote ALKINDI SPRINKLE (search) (hydrocortisone), KHINDIVI (search) (hydrocortisone), and INCRELEX (mecasermin), will handle promotion.
Patient Access and Support Programs
The Eton Cares Program, administered through Anovo (search), will provide comprehensive patient support including prescription fulfillment, insurance benefits investigation, educational support, and financial assistance for qualified patients. The program offers co-pay assistance allowing $0 co-pay for qualifying patients.
Safety Profile and Clinical Considerations
DESMODA (search) carries important safety considerations typical of desmopressin therapy. The most significant risk is hyponatremia (search), which can result from excessive fluid intake when urine output is limited by the antidiuretic effect. Severe hyponatremia may result in seizures, coma, respiratory arrest, or death.
Fluid restriction is recommended during treatment and is particularly important in pediatric and geriatric patients, who face increased risk. The product is contraindicated in patients with hypersensitivity to desmopressin acetate, moderate to severe renal impairment, or hyponatremia (search) history.
Additional precautions include careful use in patients with heart failure or uncontrolled hypertension, and special monitoring for low-birth-weight neonates and preterm neonates due to benzoic acid content.
Indication and Limitations
DESMODA (search) is indicated for the management of central diabetes insipidus (search) as antidiuretic replacement therapy for adults and pediatric patients. The product is not approved for treating nephrogenic diabetes insipidus (search), representing a key limitation of use.
Central diabetes insipidus (search) is a rare but serious condition caused by inadequate production of vasopressin hormone from the hypothalamus/posterior pituitary. Treatment with desmopressin represents the standard of care, but dosing must be individualized to avoid complications related to over- or under-treatment.